Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.

Abstract

OBJECTIVE:

The purpose of this study was to assess changes in the tumor microvasculature induced by combination antiangiogenic therapy in MCF-7 breast tumor mouse models, using a noninvasive DCE-MRI method that minimizes the effect of water exchange.

MATERIALS AND METHODS:

3D quantitative DCE-MRI images were acquired with a heavily T1-weighted saturation recovery gradient echo sequence with a recovery delay of 20 ms. Tumor vascular volume (VV) and vascular permeability-surface area product (PS) were obtained through a linear regression of the albumin-Gd-DTPA-enhanced dynamic image intensity on MCF-7 breast tumor mouse models treated with combination bevacizumab/paclitaxel therapy.

RESULTS:

Measured tumor VV values were significantly higher than the values that have been reported previously using quantitative T1 mapping, and are in good agreement with micro-CT (computed tomography) results reported earlier from other tumor models. A trend of decreasing tumor PS was detected in the group of MCF-7 tumor bearing mice treated with the bevacizumab/paclitaxel combination regimen.

CONCLUSION:

VV and PS maps obtained by a heavily T1-weighted acquisition protocol revealed the large peripheral blood vessels as well as the permeable areas within the tumor. A 12-day/three-dose combination treatment of bevacizumab and paclitaxel resulted in delayed tumor growth and a trend of decreasing tumor vascular permeability surface area product.

• Authors: Wenlian Zhu, Yoshinori Kato, Dmitri Artemov
• Journal: Magma (New York, N.Y.) (MAGMA) Vol. 27 Issue 2 Pg. 161-70 (Apr 2014) ISSN: 1352-8661 [Electronic] Germany
• PMID: 23807596 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Bevacizumab
• Paclitaxel

Topics

• Algorithms
• Angiogenesis Inhibitors (administration & dosage)
• Animals
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Agents (administration & dosage)
• Artifacts
• Bevacizumab
• Body Water (metabolism)
• Female
• Humans
• Image Enhancement (methods)
• Image Interpretation, Computer-Assisted (methods)
• Imaging, Three-Dimensional (methods)
• MCF-7 Cells
• Magnetic Resonance Imaging (methods)
• Mice
• Mice, SCID
• Neoplasms, Experimental (drug therapy, metabolism, pathology)
• Neovascularization, Pathologic (drug therapy, metabolism, pathology)
• Paclitaxel (administration & dosage)
• Reproducibility of Results
• Sensitivity and Specificity
• Treatment Outcome